Editorial

Treat to Target in the Management of Chronic Uveitis

Uveitis is a cause of visual loss in 10% of the visually handicapped. The etiology of uveitis remains unknown in about 50% of cases. The most important diseases behind endogenous uveitis are spondyloarthropathies, juvenile idiopathic arthritis (JIA), sarcoidosis, multiple sclerosis, and tubulointerstitial nephritis. Uveitis may be caused by infectious agents such as toxoplasma, herpes viruses, Borrelia burgdorferi, cytomegaloviruses, tuberculosis, and syphilis. If the etiology is known, the treatment strategy is according to the underlying disease1,2,3.

The treatment of chronic endogenous uveitis is frequently difficult. The first-line standard therapy for uveitis is topical, periocular, and systemic corticosteroids; and often methotrexate (MTX), as a second-line disease-modifying antirheumatic drug (DMARD). Tumor necrosis factor-α (TNF-α) blockers have been used to treat uveitis associated with JIA in children who have failed conventional topical and immunosuppressive therapy. Infliximab and adalimumab, in particular, have been shown to be effective for chronic uveitis, frequently in combination with MTX, to increase the treatment effect and to decrease the risk of development of neutralizing antibodies against the TNF-blocker. If MTX is not tolerated or is ineffective, azathioprine, leflunomide, cyclosporin A, or mycophenolate mofetil may be used. Other biologic drugs, such as abatacept, tocilizumab, rituximab, and golimumab, may be beneficial in severe uveitis4,5.

In this issue of The Journal, Pelegrin, et al. report promising results of rituximab treatment in 9 patients with uveitis who were refractory to standard immunosuppressive treatment. Rituximab was effective and induced clinical remission of uveitis in most patients.

Treatment experiences of DMARD combination are also described in this issue for treatment of childhood uveitis. Little, et al. examined the effect of combining a third immunosuppressive drug with the conventional immunosuppressive treatment, which mainly consisted of MTX and TNF-α blocker. In their 13 uveitis patients, triple therapy did not confer substantial benefit for chronic uveitis; instead the therapy was associated with increased risk of infectious adverse effects.

The treatment of chronic uveitis is challenging. The model of the treat-to-target approach in the management of JIA may also be suitable for the treatment of uveitis: early and aggressive treatment of uveitis to achieve clinical remission and even disease inactivation8. This could be accomplished by strict monitoring of patients with uveitis by uveitis specialists, in close cooperation with rheumatologists, pediatric rheumatologists, internists, and immunologists.

In the near future, more reports of uveitis treatment with new biologic drugs are anticipated; hopefully, prospective, comparative, controlled studies to manage this severe disease will mean even better results than today. Despite the sometimes high costs of drugs, the basic goal of treatment is to prevent blindness in these patients.

KAISU KOTANIEMI, MD, PhD,
Department of Ophthalmology,
Helsinki University Hospital,
Helsinki, Finland.

Address correspondence to Dr. Kotaniemi.
E-mail: kaisukotaniemi@gmail.com

REFERENCES

See Rituximab for ocular autoimmune diseases, page 84
and Triple therapy in pediatric uveitis, page 136

© 2014 The Journal of Rheumatology

